To address these gaps, this study aimed to compare the outcomes of early versus late switching from anti-VEGF therapy to DEX implants in patients with macular edema secondary to CRVO, with a particular focus on the role of OCT in guiding these therapeutic decisions. Here, VEGFA is linked to macular retinal edema.